Navigation Links
Watson and Richter Announce Exclusive License Agreement for Esmya™
Date:12/16/2010

MORRISTOWN, N.J., and BUDAPEST, HUNGARY, Dec. 16, 2010 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) ("Watson") and Gedeon Richter Plc ("Richter") today announced that Watson's subsidiary, Watson Laboratories, Inc. has entered into an exclusive licensing agreement with PregLem, S.A., ("Preglem") the wholly owned subsidiary of Richter, to develop and market Esmya™ (ulipristal acetate) in the U.S. and Canada.  In European studies, Esmya™ has been shown to be an effective and safe treatment for uterine fibroids (myoma), a condition that affects millions of women worldwide. The product is currently in late stage development in Europe and Watson expects to initiate U.S. Phase III clinical studies in 2011.

Under terms of the agreement, Watson will pay PregLem a $17 million license fee and will pay royalties based on sales in the U.S. and Canada. Watson will make additional payments based on the achievement of certain regulatory milestones. The companies will also collaborate on additional Esmya™ formulations, jointly sharing the development costs.

"Esmya™ represents a significant strategic addition to our portfolio of women's health products and is potentially the first effective treatment for uterine fibroids in more than 20 years," said Paul Bisaro, Watson's Chief Executive Officer.  "The agreement enables us to maximize our expertise in developing, registering and commercializing significant therapeutic advances in diseases treated by OB/GYNs.  It also forms the foundation for us to further develop a franchise of products and indications in the uterine fibroid category.  We look forward to further expanding our relationship with PregLem and Gedeon Richter for future opportunities between our companies."

"I am pleased with the agreement concluded with Watson, as their specialty knowledge and marketing
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  The Partnership to Fight Chronic Disease (PFCD) released a public ... and a new study analyzing the impact of increased cost sharing ... coalition working to educate policy makers and the public on the ... focused on how the Iowa healthcare exchange ...
(Date:1/23/2015)... BETHESDA, Md. , Jan. 23, 2015  Northwest Biotherapeutics, Inc. ... developing DCVax® personalized immune therapies for operable and inoperable solid ... will present at the 7 th Annual Phacilitate Immunotherapy ... NW Bio,s presentation at Phacilitate will take place on January ...
(Date:1/23/2015)... than a third of reproductive-aged women enrolled in Medicaid, and ... a prescription for an opioid pain medication each year during ... Mortality Weekly Report (MMWR). Opioids are typically ... pain.  They are also found in some prescription cough medications. ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... 25, 2011 PDI, Inc. (Nasdaq: ... and commercialization services to health care companies, today announced ... 10 pharmaceutical company has been renewed for an additional ... Shared Sales team beginning in September 2011 through March ...
... 2011 Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN ) ... who has conducted multiple clinical studies of zinc lozenges for the ... Mr. Eby is a pioneer in the development of zinc ... more than 30 years to the study of zinc and is ...
Cached Medicine Technology:PDI Announces Renewal of Engagement for 7th Consecutive Season 2Adeona Appoints George A. Eby to Scientific Advisory Board 2Adeona Appoints George A. Eby to Scientific Advisory Board 3Adeona Appoints George A. Eby to Scientific Advisory Board 4
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
(Date:1/22/2015)... 2015 Four years since the release of their ... with the marriage of Avasa & Matthew Love – the duo ... scheduled for release through White Swan Records on February 24, 2015. ... a sacred path available to all of us to walk out ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
(Date:1/22/2015)... 2015 Lower-Auto-Insurance.com has released a new blog post ... car for reducing the costs of an auto insurance policy ... able to get lower prices for their vehicle insurance policies. The ... in determining policy costs. Because of this, drivers should always ...
(Date:12/26/2014)... The US represents the largest market for CRC across ... estimates that sales of branded therapies were $2.23 billion. The ... incidence of the disease, high drug treatment rate, and higher ... sales of CRC therapies over the forecast period will be ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... to Present September,22-24, 2008, WASHINGTON, Sept. ... medical technology companies have been selected to ... presentations offer a unique,business development and information ... the cardiovascular, dental, diagnostics, imaging,metabolic disease/obesity, neurology, ...
... - U.S. Preventive Medicine, Inc.,( http://www.USPreventiveMedicine.com ), the ... Ron Loeppke, M.D., MPH, as Co-Chairman of,the company,s ... researching,the role of primary, secondary and tertiary prevention ... health and,productivity in the workplace, as well as ...
... 1 in U.S. ... ... Inc. and Orphan Therapeutics, LLC announced today that they have,entered into an ... from Orphan Therapeutics., Orphan Therapeutics has initiated a rolling NDA with ...
... 2 The Diversified Agency Services (DAS),unit ... to the position of,Executive Vice President and ... position Sharon will direct the client-centric and,brand-centric ... a,worldwide multidisciplinary resource of specialist agencies that ...
... Sept. 2 September is Cholesterol,Awareness Month. The ... perceived failures in drug trials, Tim Russert,s sudden,death, ... of dyslipidemia in,children have all led to increased ... views these developments as reinforcing the importance of ...
... finding is ,good news, for postmenopausal women taking ... Contrary to previous study results, the cancer prevention ... of cognitive performance, a new study found. ... to tamoxifen in preventing breast cancer recurrence in ...
Cached Medicine News:Health News:Canadian, German, Israeli, New Zealand, U.K and U.S. Companies Selected to Make Company Presentations at AdvaMed 2008 2Health News:Canadian, German, Israeli, New Zealand, U.K and U.S. Companies Selected to Make Company Presentations at AdvaMed 2008 3Health News:Canadian, German, Israeli, New Zealand, U.K and U.S. Companies Selected to Make Company Presentations at AdvaMed 2008 4Health News:U.S. Preventive Medicine Appoints Ron Loeppke, M.D. as Co-Chairman of Its National Advisory Board 2Health News:U.S. Preventive Medicine Appoints Ron Loeppke, M.D. as Co-Chairman of Its National Advisory Board 3Health News:Ikaria(R) Acquires North American Rights to LUCASSIN(R) From Orphan Therapeutics 2Health News:Ikaria(R) Acquires North American Rights to LUCASSIN(R) From Orphan Therapeutics 3Health News:Sharon Callahan Joins Diversified Agency Services Unit of Omnicom Group 2Health News:Cholesterol Awareness Month: Americans Urged to Seek Early Intervention 2Health News:Breast Cancer Drug Not Tied to Cognitive Decline: Study 2
... Artis FC is a floor-mounted, ... flexible system architecture for vascular ... The flexible and ergonomic system ... adapt the system configuration to ...
The ACUSON Sequoia C512 system elevates imaging and Doppler performance through new, high-density acoustic sampling, precise control of the transmitted acoustic waveform, and new transducer technolog...
... cardioangiography procedures with MR imaging results and ... Utilize your angio and MR system at ... suite. Because the systems can be combined ... follow-up in one room, one control room ...
... every beating heart at any heart rate and ... scanner using two X-ray sources and two detectors ... in acute care; even with large patients, regardless ... Cardiac Engine, a unique combination of Siemens innovative ...
Medicine Products: